Biomarker science evolves quickly. Clinical guidelines are refined, consensus statements are updated, and laboratory standards become more harmonized over time. As the evidence changes, the way biomarker results are interpreted also needs to evolve.
At Biostarks, this means our work does not stop once a biomarker is available in a report. We continuously review how each result is interpreted, where the reference ranges come from, and whether the thresholds we use still reflect the best available evidence.
We have now completed a full review of the reference ranges behind every primary biomarker we report. The update realigns our interpretation framework with the most current tier-1 evidence, including 2024 and 2025 clinical guidelines, consensus statements, and harmonized laboratory standards.
It also refines how biomarker results move across our graduated interpretation zones:
optimal → in range → to monitor → out of range
This framework was already part of Biostarks, but the update makes it more realistic and data-driven, especially for biomarkers that are often reported elsewhere as simple binary outcomes.
In practice, this means not every deviation from an optimal zone is treated the same. A mildly elevated Vitamin D result, for example, should not be interpreted in the same way as a true deficiency. One may simply sit in a benign to monitor zone, while the other may carry a clearer biological or clinical concern.
The update helps preserve that distinction across the platform: identifying meaningful risk where it matters, while avoiding unnecessary alarm when a result is outside an optimal band but not genuinely problematic.
Why Reference Ranges Need to Evolve
Reference ranges are not static. Some are based on population averages. Others are based on clinical risk thresholds. Others reflect functional or preventive targets, where the question is not only whether a result is abnormal, but also whether it is aligned with better long-term health.
That distinction matters. A lipid marker may sit within a broad population reference range while still being above the optimal target used in modern cardiovascular prevention. A glycemic marker may not yet meet a diagnostic threshold for diabetes, but may already show early movement toward metabolic risk. A vitamin level may sit above a classic sufficiency threshold without being anywhere near a toxicity concern.
Our updated framework is designed to reflect those differences more clearly.
What Changed
Cardiovascular lipids: aligned with modern prevention targets
We reviewed LDL cholesterol, ApoB, Lp(a), TC/HDL ratio, atherogenic indices, and ceramide risk markers against the ESC/EAS dyslipidaemia framework and the EAS Lp(a) consensus.
The main conceptual shift is that cardiovascular interpretation has increasingly moved away from population-average normal ranges and toward lower, risk-based optimal targets. In practice, this means LDL and ApoB are interpreted with a stronger prevention lens: not only whether they are statistically common in the population, but whether they are aligned with current cardiovascular risk-reduction standards. These markers sit at the core of our Metabolic Health panel.
Glycemic control and insulin resistance: earlier visibility on metabolic drift
Fasting glucose, HbA1c, HOMA-IR, TyG, and QUICKI were reviewed against the ADA 2025 Standards of Care.
We added more graduated buffers between optimal values and diagnostic diabetes thresholds, making early movement toward insulin resistance or prediabetic physiology easier to identify. The goal is not to over-medicalize small changes. It is to make metabolic drift visible before it becomes more advanced.
Vitamin D: updated to the 2024 Endocrine Society position
Vitamin D interpretation has changed meaningfully in recent years. The older idea that 30 ng/mL should be used as a universal hard sufficiency threshold has been de-emphasized in the latest literature. We updated our Vitamin D framework to reflect the 2024 Endocrine Society guideline while preserving a practical functional interpretation.
The new structure includes an optimal window, a benign supra-optimal band, and an out-of-range flag reserved for values approaching the genuine toxicity edge, not an abrupt warning just above the optimal zone.
Omega-3 and fatty-acid status: more nuance on inflammatory balance
The Omega-3 Index keeps its evidence-based optimal target of at least 8%, supported by the Harris and von Schacky framework.
We also upgraded the AA:EPA ratio from a simple in/out flag to a four-zone structure. This gives a more graduated interpretation of fatty-acid balance and inflammatory tone, rather than treating all deviations as equivalent. Vitamin D and the Omega-3 Index are both part of our Nutrition panel.
Amino acids: standardized to plasma reference intervals
The amino acid panel was standardized to the plasma matrix and re-anchored to reference-lab intervals from major clinical laboratories, including Mayo, LabCorp, and UI Health.
Several outdated or broken source links were replaced, and population bounds were recomputed consistently across the panel. This improves comparability and reduces inconsistencies between markers that belong to the same biological family.
Hormones: stratified by sex, age, and clinical context
Hormone ranges were retained and verified where sex- and age-specific interpretation is required, including testosterone, estradiol, DHEA-S, SHBG, IGF-1, TSH, and related markers. These were checked against Endocrine Society guidance and CDC-harmonized data where applicable.
We also corrected aldosterone, which previously had an incomplete range definition, and aligned it with the Endocrine Society primary aldosteronism reference framework.
Kidney function: aligned with KDIGO 2024
eGFR, cystatin C, SDMA, and urea nitrogen were reviewed against KDIGO 2024.
One important correction concerns SDMA: only elevated SDMA is now treated as clinically meaningful. Low SDMA values are no longer flagged as if they carried the same interpretive weight.
Neurology and early Alzheimer's proteomics
p-tau217 and the p-tau217 ratio were updated to clinically validated PrecivityAD2 and Lumipulse cutpoints. The updated interpretation includes an explicit indeterminate zone between negative and positive thresholds, supporting more appropriate monitoring when a result does not clearly fall into either category.
Toxicology and exposure markers
PEth, a marker of alcohol exposure, was aligned to the 2022 PEth-NET Consensus of Basel.
For toxicology and exposure markers, we keep hard upper cutoffs by design. Unlike nutrients or functional markers, these do not have a benign high but still favorable zone.
Behind the Scenes: Consistency Across 1,435 Biomarkers
Beyond the 63 primary clinical updates, we also completed a system-wide consistency pass across all 1,435 biomarkers in our database. This included:
- recomputing population reference intervals consistently from optimal and in-range zones;
- normalizing matrix labels;
- tightening continuity between bands;
- reducing abrupt status transitions;
- improving consistency across related biomarkers.
This is mostly invisible infrastructure work, but it matters. It makes every result easier to interpret and reduces the risk of inconsistent classification between markers.
What This Means for Users and Partners
For users, the result is a clearer and more progressive interpretation of biomarker status.
For clinicians and professional partners, it means our reports are better aligned with current clinical frameworks, while still preserving the preventive and longitudinal perspective that makes biomarker tracking useful.
For Biostarks, this update reflects a core principle: a biomarker platform should not only measure well. It should also interpret responsibly, transparently, and in line with the evolving scientific standard.
Important Note
This update concerns reference ranges and interpretation zones. It does not change the underlying analytical measurement of your biomarkers.
As always, Biostarks reports are intended to support health awareness, prevention, and informed conversations with qualified professionals. They are not a substitute for medical diagnosis or individualized medical advice.
In Summary
We refreshed the reference ranges behind our biomarkers to reflect the latest 2024 and 2025 clinical guidelines and consensus standards. We also made the interpretation framework more realistic and data-driven.
Rather than treating every deviation from an optimal range as equivalent, the updated ranges better distinguish between results that are simply worth monitoring and results that may carry clearer biological or clinical concern.
This is part of our ongoing commitment to keeping biomarker interpretation clinically grounded, scientifically current, and useful in real life.
